TELCON RF PHARMACEUTICAL (A200230) Stock Overview
Primarily engages in the development, production, and sale of RF coaxial connectors worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A200230 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TELCON RF PHARMACEUTICAL. Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩973.00 |
| 52 Week High | ₩4,433.33 |
| 52 Week Low | ₩930.00 |
| Beta | 0 |
| 1 Month Change | -14.57% |
| 3 Month Change | -46.68% |
| 1 Year Change | -48.61% |
| 3 Year Change | -74.84% |
| 5 Year Change | -95.38% |
| Change since IPO | -75.16% |
Recent News & Updates
More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%
Sep 11
TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With Revenues
Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too Soon
Mar 24Recent updates
More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%
Sep 11TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With Revenues
Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too Soon
Mar 24TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From Overpricing
Oct 23TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A Company
Sep 06Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Earnings
Mar 26TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than Expected
Mar 13Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?
Apr 05Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?
Feb 03Shareholder Returns
| A200230 | KR Electronic | KR Market | |
|---|---|---|---|
| 7D | 2.2% | 7.4% | 2.4% |
| 1Y | -48.6% | 55.7% | 57.3% |
Return vs Industry: A200230 underperformed the KR Electronic industry which returned 55.8% over the past year.
Return vs Market: A200230 underperformed the KR Market which returned 57.2% over the past year.
Price Volatility
| A200230 volatility | |
|---|---|
| A200230 Average Weekly Movement | 12.4% |
| Electronic Industry Average Movement | 6.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A200230's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A200230's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 124 | Jin-Hun Lim | www.telcon.co.kr |
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals.
TELCON RF PHARMACEUTICAL. Inc. Fundamentals Summary
| A200230 fundamental statistics | |
|---|---|
| Market cap | ₩35.07b |
| Earnings (TTM) | -₩33.51b |
| Revenue (TTM) | ₩43.68b |
Is A200230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A200230 income statement (TTM) | |
|---|---|
| Revenue | ₩43.68b |
| Cost of Revenue | ₩32.04b |
| Gross Profit | ₩11.64b |
| Other Expenses | ₩45.15b |
| Earnings | -₩33.51b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -929.50 |
| Gross Margin | 26.65% |
| Net Profit Margin | -76.71% |
| Debt/Equity Ratio | 31.4% |
How did A200230 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/30 02:05 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TELCON RF PHARMACEUTICAL. Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Ju Park | Daishin Securities Co. Ltd. |